## SUPPLEMENTARY MATERIAL

**Supplementary Table S1.** Sequence and concentration of primers used for qPCR.

Gene	Forward primer	Reverse primer	Concentration	
TGFβ	GCGTGCTAATGGTGGAAACC	GCTTCTCGGAGCTCTGATGTG	150nM	
IL-1β	ACCTGAGCACCTTCTTTCCC	TCGTGCACATAAGCCTCGTT	300nM	
IL-4	TAGGCTGAAAGGGGGAAAGC	CTGTTCACCTCAACTGCTCC	600nM	
TNF-	GCTGTACCTTATCTACTCCC	CTCCTGGTATGAAATGGC	600nM	
HPRT	GAACGTCTTGCTCGAGATGTGA	TCCAGCAGGTCAGCAAAGAAT	150nM	

## Supplementary Table S2 Characteristics of patients.

Patient	Age/Sex	Cytogenetics	Chemotherapy combined with green tea	Time of therapy before cytarabine (days)	Time under green tea therapy (days)	Number of hospitalizations	Total days at hospital
#1	79/M	46XY, del(9) (q31-34)	No	-	425	1	28
#2	80/F	COMPLEX	No	-	229	1	13
#3	76/M	46XY	Yes	150	657	1	10
#4	87/M	COMPLEX	Yes	60	303	1	7
#5	70/F	48XX, +4, +14	Yes	60	832	3	36
#6	68/F	46XX	No	-	413	4	58
#7	84/M	48XY, +8	No	-	50	1	5
#8	64/M	COMPLEX	No	-	49	1	6
#9	78/M	Na	Yes	60	226	2	50
#10	68/M	46XY	Yes	60	72	1	7

During the study, three patients passed away before completing the study (patients #7, #8, #10). Low-dose cytarabine was introduced in patients at day 60 (n=4; patient #4, #5, #9, #10) and at day 150 (n=1; patient #3); however, one patient lacked in measurements (patient #9) and one patient passed away before completing treatment (patient #10). Three patients did not need to receive low-dose cytarabine during this study being treated with green tea alone (patient #1, #2, #6); however, one patient lacked in measurements (patient #6).